Research Pipeline
Four development programs targeting neuroprotection across distinct at-risk populations. All based on the same core lipid supplementation platform.
Development Phases
Discovery
Mechanism characterization, lipid target identification, biomarker development
Preclinical
In vitro and in vivo safety, efficacy, and biomarker validation studies
Phase I
First-in-human safety, tolerability, and PK/PD studies in healthy volunteers
Phase II
Proof-of-concept efficacy in target populations with biomarker endpoints
Phase III
Pivotal efficacy and safety trials for regulatory approval
Development Programs
Blast TBI Prevention in Warfighters
NS-001 targets modification of neuronal membrane DHA and plasmalogen content in military personnel at sustained blast exposure risk. Preclinical models demonstrate reduced neuroinflammatory response and preserved cognitive performance following simulated blast events in supplemented animals.
Target Populations
- Active duty military
- Combat-exposed personnel
Current Milestone
IND-enabling studies in progress
Cumulative Impact Neuroprotection in Contact Athletes
NS-002 is designed for the contact sport athlete population, targeting the subconcussive impact accumulation that precedes detectable clinical injury. Rodent repetitive impact models show significant reduction in white matter injury markers and behavioral deficits in treated animals.
Target Populations
- Professional contact sport athletes
- Collegiate athletes
Current Milestone
Dose-response characterization ongoing
Age-Associated Membrane Decline and Fall-Related TBI
NS-003 addresses the natural decline in neuronal membrane plasmalogen content with aging, which substantially increases vulnerability to injury from falls and minor head trauma. Discovery work is characterizing the lipid deficiency profile across age cohorts to identify optimal supplementation targets.
Target Populations
- Adults 65+
- Assisted living populations
Current Milestone
Lipid profiling studies underway
First Responder Occupational Neurological Risk
NS-004 addresses cumulative neurological burden in first responders from blast exposure (firefighting), repeated physical trauma, and toxic environmental exposures. Epidemiological work is characterizing biomarker burden in active first responders to inform membrane-targeted intervention design.
Target Populations
- Firefighters
- Law enforcement
- Emergency medical personnel
Current Milestone
Epidemiological study design phase
Platform Approach
All four NeuroShield Sciences programs are built on the same foundational platform: oral lipid supplementation that modifies neuronal plasma membrane composition through established lipid transport pathways. This platform approach means that efficacy demonstrated in one population generates meaningful evidence for the others, and manufacturing, regulatory, and clinical development capabilities are shared across the pipeline.
The modality (oral supplement) is well-tolerated, scalable, and appropriate for the prophylactic use case: protecting individuals before injury occurs, not treating them after.
Collaborate on Our Pipeline
We are actively seeking clinical site partners, academic collaborators, and strategic partners across all four programs.